Fust Matthew K
SEC-identified person · CIK 1397266 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Crinetics Pharmaceuticals, Inc. CRNX | Director | filed 2018 - 2026 |
| Atara Biotherapeutics, Inc. ATRA | Director | filed 2014 - 2026 |
| Neumora Therapeutics, Inc. NMRA | Director | filed 2023 - 2026 |
| Ultragenyx Pharmaceutical Inc. RARE | Director | filed 2014 - 2026 |
| Dermira, Inc. DERM | Director | filed 2014 - 2020 |
| Macrogenics INC MGNX | Director | filed 2014 - 2019 |
| Onyx Pharmaceuticals INC ONXX | EVP & Chief Financial Officer | filed 2009 - 2013 |
| Jazz Pharmaceuticals plc JAZZ | Senior Vice President & CFO | filed 2007 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.